Literature DB >> 33729203

How Many SARS-CoV-2-Infected People Require Hospitalization? Using Random Sample Testing to Better Inform Preparedness Efforts.

Nir Menachemi1, Brian E Dixon, Kara K Wools-Kaloustian, Constantin T Yiannoutsos, Paul K Halverson.   

Abstract

CONTEXT: Existing hospitalization ratios for COVID-19 typically use case counts in the denominator, which problematically underestimates total infections because asymptomatic and mildly infected persons rarely get tested. As a result, surge models that rely on case counts to forecast hospital demand may be inaccurately influencing policy and decision-maker action.
OBJECTIVE: Based on SARS-CoV-2 prevalence data derived from a statewide random sample (as opposed to relying on reported case counts), we determine the infection-hospitalization ratio (IHR), defined as the percentage of infected individuals who are hospitalized, for various demographic groups in Indiana. Furthermore, for comparison, we show the extent to which case-based hospitalization ratios, compared with the IHR, overestimate the probability of hospitalization by demographic group.
DESIGN: Secondary analysis of statewide prevalence data from Indiana, COVID-19 hospitalization data extracted from a statewide health information exchange, and all reported COVID-19 cases to the state health department.
SETTING: State of Indiana as of April 30, 2020. MAIN OUTCOME MEASURES: Demographic-stratified IHRs and case-hospitalization ratios.
RESULTS: The overall IHR was 2.1% and varied more by age than by race or sex. Infection-hospitalization ratio estimates ranged from 0.4% for those younger than 40 years to 9.2% for those older than 60 years. Hospitalization rates based on case counts overestimated the IHR by a factor of 10, but this overestimation differed by demographic groups, especially age.
CONCLUSIONS: In this first study of the IHR based on population prevalence, our results can improve forecasting models of hospital demand-especially in preparation for the upcoming winter period when an increase in SARS CoV-2 infections is expected.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33729203     DOI: 10.1097/PHH.0000000000001331

Source DB:  PubMed          Journal:  J Public Health Manag Pract        ISSN: 1078-4659


  15 in total

1.  Home management of COVID-19 symptomatic patients: a safety study on COVID committed home medical teams.

Authors:  Sergio Venturini; Daniele Orso; Francesco Cugini; Francesco Martin; Cecilia Boccato; Laura De Santi; Elisa Pontoni; Silvia Tomasella; Fabrizio Nicotra; Alessandro Grembiale; Maurizio Tonizzo; Silvia Grazioli; Sara Fossati; Astrid Callegari; Giovanni Del Fabro; Massimo Crapis
Journal:  Infez Med       Date:  2022-09-01

2.  COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods.

Authors:  Florian B Mayr; Victor B Talisa; Alexander D Castro; Obaid S Shaikh; Saad B Omer; Adeel A Butt
Journal:  Nat Commun       Date:  2022-06-25       Impact factor: 17.694

3.  Use of COVID-19 Test Positivity Rate, Epidemiological, and Clinical Tools for Guiding Targeted Public Health Interventions.

Authors:  Nivedita Gupta; Salaj Rana; Samiran Panda; Balram Bhargava
Journal:  Front Public Health       Date:  2022-03-16

4.  Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.

Authors:  Jonathon W Senefeld; Patrick W Johnson; Katie L Kunze; Evan M Bloch; Noud van Helmond; Michael A Golafshar; Stephen A Klassen; Allan M Klompas; Matthew A Sexton; Juan C Diaz Soto; Brenda J Grossman; Aaron A R Tobian; Ruchika Goel; Chad C Wiggins; Katelyn A Bruno; Camille M van Buskirk; James R Stubbs; Jeffrey L Winters; Arturo Casadevall; Nigel S Paneth; Beth H Shaz; Molly M Petersen; Bruce S Sachais; Matthew R Buras; Mikolaj A Wieczorek; Benjamin Russoniello; Larry J Dumont; Sarah E Baker; Ralph R Vassallo; John R A Shepherd; Pampee P Young; Nicole C Verdun; Peter Marks; N Rebecca Haley; Robert F Rea; Louis Katz; Vitaly Herasevich; Dan A Waxman; Emily R Whelan; Aviv Bergman; Andrew J Clayburn; Mary Kathryn Grabowski; Kathryn F Larson; Juan G Ripoll; Kylie J Andersen; Matthew N P Vogt; Joshua J Dennis; Riley J Regimbal; Philippe R Bauer; Janis E Blair; Zachary A Buchholtz; Michaela C Pletsch; Katherine Wright; Joel T Greenshields; Michael J Joyner; R Scott Wright; Rickey E Carter; DeLisa Fairweather
Journal:  PLoS Med       Date:  2021-12-20       Impact factor: 11.069

5.  COVID-19 Prevalence among Czech Dentists.

Authors:  Jan Schmidt; Vojtech Perina; Jana Treglerova; Nela Pilbauerova; Jakub Suchanek; Roman Smucler
Journal:  Int J Environ Res Public Health       Date:  2021-11-27       Impact factor: 3.390

6.  Antibody therapies for treatment of non-severe COVID-19.

Authors:  Katie Gourlay; Nicholas Taylor; Eddy Lang
Journal:  Intern Emerg Med       Date:  2022-03-16       Impact factor: 5.472

7.  Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies.

Authors:  Daniel Herrera-Esposito; Gustavo de Los Campos
Journal:  BMC Infect Dis       Date:  2022-03-29       Impact factor: 3.090

8.  Pandemic trends in health care use: From the hospital bed to self-care with COVID-19.

Authors:  Fredrik Methi; Kjersti Helene Hernæs; Katrine Damgaard Skyrud; Karin Magnusson
Journal:  PLoS One       Date:  2022-03-23       Impact factor: 3.240

9.  Individualized Constellation of Killer Cell Immunoglobulin-Like Receptors and Cognate HLA Class I Ligands that Controls Natural Killer Cell Antiviral Immunity Predisposes COVID-19.

Authors:  Stalinraja Maruthamuthu; Karan Rajalingam; Navchetan Kaur; Maelig G Morvan; Jair Soto; Nancy Lee; Denice Kong; Zicheng Hu; Kevin Reyes; Dianna Ng; Atul J Butte; Charles Chiu; Raja Rajalingam
Journal:  Front Genet       Date:  2022-02-22       Impact factor: 4.599

10.  SARS-CoV-2 active infection prevalence and seroprevalence in the adult population of St. Louis County.

Authors:  Charles W Goss; Brett B Maricque; Victoria V Anwuri; Rachel E Cohen; Kate Donaldson; Kimberly J Johnson; William G Powderly; Kenneth B Schechtman; Spring Schmidt; Jeannette Jackson Thompson; Anne M Trolard; Jinli Wang; Elvin H Geng
Journal:  Ann Epidemiol       Date:  2022-03-08       Impact factor: 6.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.